Sun Pharma: Touching Lives Globally As a Leading Provider of Valued Medicines

Kirti Ganorkar, CEO, Sun Pharma

The global pharmaceutical industry stands at a critical inflection point, driven by rising healthcare demands, patent expiries, and the growing importance of specialty generics. As chronic and complex diseases continue to increase worldwide, manufacturers are shifting beyond volume-driven models toward high-value, research-backed formulations that ensure both efficacy and affordability.

At the same time, advancements in drug development, regulatory harmonization, and large-scale manufacturing capabilities are enabling faster market access across geographies. The industry is also witnessing a stronger emphasis on patient-centric care, improved accessibility, and innovation-led growth.

In this evolving landscape, pharmaceutical companies are not only expanding their global reach but also redefining how quality medicines are developed, produced, and delivered at scale.

This is where Sun Pharma, a leading global specialty generic company comes into the picture. With global revenue of US$ 6.2 billion and supported by 41 manufacturing facilities, the company offers high-quality medicines, which are trusted by healthcare professionals and patients, and supplies it to more than 100 countries worldwide. With 1,000 Sun Pharma medicines prescribed every minute, the company is driven by a commitment to innovation, enhanced access and patient care.

Sun Pharma produces as well as markets a large basket of pharmaceutical formulations across chronic and acute therapies. This includes specialty & complex products, generics, APIs, over-the-counter, intermediates, branded generics, and antiretrovirals. The company’s portfolio spans numerous dosage forms.

These include injectables, creams, tablets, liquids, inhalers, ointments, and capsules. Sun Pharma is helping improve access to medicine worldwide with billions of doses delivered annually across its key therapeutic areas. These include cardiology, gastroenterology, dermatology, nephrology, neuro-psychiatry, anti-infectives diabetology, oncology, ophthalmology, urology, respiratory, and more.

We are committed to touching lives across the world by making trusted, value-driven medicines accessible, while continuously advancing innovation and excellence in healthcare

Sun Pharma invests around 6 - 8% of its global revenues annually into its R&D, the first among Indian pharmaceutical companies to realize and embrace the importance of innovation. With a team of over 2,900 R&D personnel with strong intellectual capabilities in formulations, process chemistry, and analytical development, the company’s strength lies in developing generics and technologically complex products.

It specializes in differentiated products which include lyophilized injections, nasal sprays, liposomal drugs, inhalers, & controlled-release dosage forms, showcasing Sun Pharma’s strong focus on innovation.

Sun Pharma has established itself into a leading specialty generic company globally and is the No. 1 pharmaceutical firm in India. In the U.S., Sun Pharma is amongst the leading specialty generic companies and is ranked No. 2 in generic dermatology by prescriptions.

It has a presence in 80 countries across emerging markets, such as Russia, Romania, Brazil, Mexico, and South Africa being some of its key markets. The company maintains a strong footprint across countries in Western Europe, Japan, New Zealand, Australia, and Canada, and Israel.

Comprehensive, Diverse & Highly Complementary Portfolio of Medicines

Sun Pharma manufactures a comprehensive, diverse as well as highly complementary portfolio of medicines targeting a wide spectrum of chronic as well as acute treatments. The company’s product portfolio comprises over-the-counter (OTC), difficult-to-make technology intensive products, branded generics, generics, specialty, anti-retrovirals (ARVs), APIs & intermediates. The company’s presence in more than 100 countries helps it in being responsive to local treatment requirements while continually enhancing its global product offering.

Enhancing Patient Outcomes

A portfolio of patent-protected specialty medicines has been built by Sun Pharma for the global markets. The company has nurtured this evolving business over the years through increased focus & investments. The key segments Sun Pharma targets include ophthalmology, dermatology, & oncology. The company’s focus is to enhance patient outcomes either by addressing unmet medical requirements or by improving patient convenience through differentiated dosage forms.

The company’s initiatives in this landscape covers the complete value chain, right from in-licensing early-to-late stage clinical candidates, as well as gaining access to on-market patented products. Today, Sun Pharma is among the leading branded firms in the United States with numerous specialty products that is launched in the country.

The Hallmark of Technology-Based Differentiation

The company offers high quality generic as well as branded medicines at affordable costs to patients & doctors in more than 100 countries across the world. Sun Pharma’s products hold the hallmark of technology-based differentiation and cover the complete range of dosage forms. These include injectables, ointments, tablets, creams and liquids, capsules, and inhalers.

The therapeutic segments of the company’s portfolio covers over 2000 molecules which include neurology, gynaecology, orthopaedic, dermatology, diabetology, psychiatry, anti-infectives, cardiology, ophthalmology, nephrology, gastroenterology, urology, respiratory, oncology, dental & nutritionals. Sun Pharma ranks among the leading companies in numerous countries in these therapy areas.

Manufacturing of Complex Formulations

As a vital input in the manufacturing of complex formulations for facilitating vertical integration, Sun Pharma began manufacturing in 1995. Today, the company’s list of Active Pharmaceutical Ingredients exceeds 400 which are used in house as well as marketed to customers in over sixty countries. The company manufactures APIs in 14 manufacturing facilities located in India, and other countries such as Hungary, the US, Israel and Australia.

Anti-Retro Viral Medications

A wide range of WHO prequalified ARV medicines are offered by Sun Pharma. Since enhancing access & affordability is the key objective of the company, it supplies ARVs to several National AIDS treatment programs in Africa. In 2004, Sun Pharma signed up with the Clinton Health Access Initiative (CHAI) in order to reduce the cost of the triple drug cocktail for consortium partners in Africa and other countries.

The portfolio of the company comprises bio-equivalent ARV medicines as well as APIs manufactured at its state-of-the-art WHO prequalified manufacturing facilities in India, a PIC/S approved manufacturing facility in South Africa and a facility in Russia.

Reaching People & Touching Lives Globally

Our Global Code of Conduct governs every aspect of our operations. Sun Pharma is a team of thousands of people, working across many countries, speaking multiple languages, and all united, with one vision: Reaching People & Touching Lives Globally as a Leading Provider of Valued Medicines.

Through active fieldwork, dedicated research teams, and in recognition of the efforts who work behind the scenes to combat illness and disease, the Sun Pharmaceutical Group helps as many people as possible, to secure their right to good health. The way we work every day is important to us.

Kirti Ganorkar, Managing Director, Sun Pharmaceutical Industries Limited

Kirti Ganorkar is the Managing Director of Sun Pharmaceutical Industries Limited, one of the world’s leading specialty generic pharmaceutical companies. A veteran of the organization, he joined Sun Pharma in 1996 and has played a pivotal role in its transformation into a global pharmaceutical leader.